# Atritech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atritech

- Industry: Medical Devices & Equipment
- Headquarters: Plymouth, US
- Website: www.atritech.net
- Total disclosed funding: $74M
- Latest round: Series E (Mar 19, 2009)
- Investors on record: 10

## About

Atritech, Inc. is a healthcare technology company focused on developing innovative solutions for cardiac arrhythmia management, striving to improve patient outcomes with their advanced medical devices.Founded in 2000 and headquartered in Plymouth, US, Atritech, Inc. specializes in cardiac care technologies. The company has undergone significant developments in its strategy and operations over the years and has completed a total of 5 deals. Its most recent deal occurred on March 3, 2011, when Boston Scientific invested in the company during a TRADE SALE that raised USD 375.00 mn, matching the total amount raised since its inception.Atritech, Inc. offers specialized medical devices focused on the management of atrial fibrillation and other cardiac arrhythmias. Their flagship product line includes innovative devices designed to enhance procedural efficiency and patient safety during cardiac interventions, primarily targeting healthcare providers and institutions involved in cardiology.The company's revenue model is based on direct sales of its medical devices to hospitals and healthcare providers. Transactions are generally made through one-time purchases, reflecting the sophisticated technology and design of their products. The emphasis is on delivering high-quality medical solutions that meet the specific needs of healthcare professionals in the cardiology sector.Atritech, Inc. plans to expand its product offerings by launching new medical devices aimed at enhancing arrhythmia management solutions in the upcoming years. The company is targeting expansion into international markets, particularly in Europe and Asia, by 2023 to capture a larger share of the growing demand for cardiac care solutions. The funding from the TRADE SALE in March 2011 will be utilized to support these growth initiatives, particularly in research and development to drive innovation.

## Funding rounds

- Series E, Mar 19, 2009, $30M — Prism Venture Management, Tullis Health Investors, Thomas, McNerney & Partners, Split Rock Partners, Vector International Limited
- Series D, Aug 29, 2007, $22M — Prism Venture Management, Tullis Health Investors, Thoma Bravo, Affinity Capital Management, St. Paul Venture Capital, SightLine Partners, Split Rock Partners, Edwards Lifesciences Corporation
- Series C, Mar 8, 2006, $22M — Prism Venture Management, Tullis Health Investors, Thoma Bravo, Affinity Capital Management, St. Paul Venture Capital, SightLine Partners

## Investors

- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series C, Series D, Series E
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series C, Series D, Series E
- Thoma Bravo (https://capitalatlas.ai/funds/thoma-bravo) — Series C, Series D
- Affinity Capital Management (https://capitalatlas.ai/funds/affinity-capital-management) — Series C, Series D
- St. Paul Venture Capital (https://capitalatlas.ai/funds/st-paul-venture-capital) — Series C, Series D
- SightLine Partners — Series C, Series D
- Split Rock Partners (https://capitalatlas.ai/funds/split-rock-partners) — Series D, Series E
- Edwards Lifesciences Corporation — Series D
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series E
- Vector International Limited — Series E